Pro-Cure  develops and commercialises new therapeutic prostate targets in collaboration with leading pharmaceutical companies operating in the prostate cancer field.

Pro-Cure has been  engaged in “value development” activities based on molecular biology based target validation and the use of its unique in-house in-vitro and in-vivo prostate cancer models  and is building a catalogue of validated targets. It is also now embarking on the development of therapeutic targets against its first targets. The company is always willing to talk to potential partners interested in entering into a collaborative research partnership or alliance which could include exclusive access to a particular set of potential drug targets.

Data on specific target sets, together with technical and collaborative support from Pro-Cure, will enable partners to accelerate new opportunities into their development pipeline which it is hoped will lead to new prostate drugs being launched.

In addition, Pro-Cure will also look to exploit the commercialisation of research opportunities in similar fields for which it has the management expertise.

In addition, Pro-Cure is also looking to exploit the commercialisation of research opportunities in other cancers.

To discuss potential opportunities please contact David Gee, our Business Development Director.